InvestLog
NVCT Nuvectis Pharma, Inc. logo

NVCT Nuvectis Pharma, Inc.

Healthcare
$10.35-5.39%ClosedMarket Cap: $274.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

17.04

P/S

0.00

EV/EBITDA

-8.82

DCF Value

$1.18

FCF Yield

-6.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-147.8%

ROA

-106.9%

ROIC

-198.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-6.0M$—
Q4 null$0.00$-7.3M$—
FY null$0.00$-26.4M$—
Q3 null$0.00$-7.5M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$10.00

Target (Median)

$10.00

Target Range

$10.00 - $10.00

2 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2025-08-04

Trading Activity

Insider Trades

View All
Shemesh Shayofficer: Chief Dev. & Ops. Officer
SellFri Jan 09
Poradosu Enriqueofficer: Chief Science & Business Off
SellFri Jan 09
Carson Michael J.officer: Vice President, Finance
SellFri Jan 09
BENTSUR RONdirector, 10 percent owner, officer: Chairman & CEO
SellFri Jan 09
Sanchez Juandirector
BuyThu Nov 06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

-0.12

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Peers

ARMP logoARMPCGEN logoCGENCRDF logoCRDFCYBN logoCYBNIPHA logoIPHAMIST logoMISTMOLN logoMOLNRANI logoRANISAVA logoSAVATNXP logoTNXP